Forman Stephen J. 4

4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jul 2, 2024

Form 4

Period: 2024-06-30

Director

Transactions

Award
Options to Purchase Common Stock
2024-06-30+3,018→ 3,018 total
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (3,018 underlying)
Award
Options to Purchase Common Stock
2024-06-30+10,000→ 10,000 total
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying)

Holdings

Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying)
5,000
Warrants to Purchase Common Stock
(indirect: By Trust)
Exercise: $57.00From: 2018-12-07Exp: 2022-12-07→ Common (2,105 underlying)
2,105
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying)
10,000
Options to Purchase Common Stock
Exercise: $9.00From: 2017-10-16Exp: 2022-10-16→ Common (833 underlying)
833
Warrants to Purchase Common Stock
(indirect: By Trust)
Exercise: $60.00From: 2018-12-07Exp: 2022-12-07→ Common (1,667 underlying)
1,667
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying)
833

Footnotes (2)

[F1]Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 10,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2024).
[F2]Effective June 30, 2024, the reporting person was granted stock options to purchase an aggregate of 3,018 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Documents

1 file